Mainz Biomed BV (MYNZ)

Name: Mainz Biomed BV (MYNZ) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Mainz Biomed BV (MYNZ)

Stock Card

$0.47

$-0.37 (-43.85%)

As on 09-Apr-2026 09:30EDT

Market cap

$11 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

10.5

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Mainz Biomed BV (MYNZ) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.46 High: 0.52

52 Week Range

Low: 0.44 High: 4.43

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-4.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-2.8
Debt to Equity

4
Book Value

$0.1
EPS

$-2.7
Face value

--
Shares outstanding

12,515,336

5 Years Aggregate

CFO

$-40.81 Mln

EBITDA

$-60.54 Mln

Net Profit

$-66.88 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Mainz Biomed BV (MYNZ)	-57.7	-42.9	-59.7	-84.5	-87.8	--	--
BSE Sensex^*	-11.7	-4.8	1.7	-7.5	3.9	5.1	9.9
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 09-Apr-2026 | *As on 09-Sep-2026 | #As on 26-Oct-2023

Company	2025	2023	2022
Mainz Biomed BV (MYNZ)	-74.1	-83.7	-31.7
S&P Small-Cap 600	4.0	13.9	-17.4
BSE Sensex	9.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Mainz Biomed BV (MYNZ)

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops... PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany. Read more

CEO & Executive Director

Mr. Guido Baechler
CEO & Executive Director

Mr. Guido Baechler
Headquarters

Mainz
Website

https://mainzbiomed.com

FAQs for Mainz Biomed BV (MYNZ)

What is the current share price of Mainz Biomed BV (MYNZ) Today?

The share price of Mainz Biomed BV (MYNZ) is $0.47 (NASDAQ) as of 09-Apr-2026 09:30 EDT. Mainz Biomed BV (MYNZ) has given a return of -87.78% in the last 3 years.

What is the current PB & PE ratio of Mainz Biomed BV (MYNZ)?

Since, TTM earnings of Mainz Biomed BV (MYNZ) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-0.41	10.47
2024	-0.19	0.69
2023	-0.02	0.19
2022	-1.94	3.63
2021	-6.41	11.78

What is the 52 Week High and Low of Mainz Biomed BV (MYNZ)?

The 52-week high and low of Mainz Biomed BV (MYNZ) are Rs 4.43 and Rs 0.44 as of 10-Sep-2026.

What is the market cap of Mainz Biomed BV (MYNZ)?

Mainz Biomed BV (MYNZ) has a market capitalisation of $ 11 Mln as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Mainz Biomed BV (MYNZ)?

Before investing in Mainz Biomed BV (MYNZ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.